A group of FDA advisors had been expected to meet on Wednesday to review expanded use of the widely-used hepatitis C drug against melanoma, the deadliest skin cancer.
WASHINGTON (Reuters) - A U.S. Food and Drug Administration advisory panel to review the use of Schering-Plough Corp's Pegintron drug to treat serious skin cancer has been postponed, the company said on Monday.
A group of FDA advisors had been expected to meet on Wednesday to review expanded use of the widely-used hepatitis C drug against melanoma, the deadliest skin cancer.
A Schering-Plough spokeswoman said the FDA was seeking clarification of existing data and no new date had been set.
(Reporting by Kim Dixon, editing by Gerald E. McCormick)
!ADVERTISEMENT!
